Repetitive transcranial magnetic stimulation for levodopa‐induced dyskinesias in Parkinson's disease
Identifieur interne : 002084 ( Main/Exploration ); précédent : 002083; suivant : 002085Repetitive transcranial magnetic stimulation for levodopa‐induced dyskinesias in Parkinson's disease
Auteurs : Saša R. Filipovi [Royaume-Uni] ; John C. Rothwell [Royaume-Uni] ; Bart P. Van De Warrenburg [Royaume-Uni, Pays-Bas] ; Kailash Bhatia [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-01-30.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Cross-Over Studies, Drug Therapy, Combination, Dyskinesia, Drug-Induced (etiology), Dyskinesia, Drug-Induced (therapy), Female, Humans, Levodopa (administration & dosage), Levodopa (adverse effects), Levodopa (therapeutic use), Male, Medical Records, Middle Aged, Motor Cortex (physiopathology), Parkinson Disease (complications), Parkinson's disease, Severity of Illness Index, Single-Blind Method, Transcranial Magnetic Stimulation (methods), Treatment Outcome, dyskinesia, placebo, transcranial magnetic stimulation.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Levodopa.
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- complications : Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- methods : Transcranial Magnetic Stimulation.
- physiopathology : Motor Cortex.
- therapy : Dyskinesia, Drug-Induced.
- Aged, Cross-Over Studies, Drug Therapy, Combination, Female, Humans, Male, Medical Records, Middle Aged, Severity of Illness Index, Single-Blind Method, Treatment Outcome.
Abstract
In a placebo‐controlled, single‐blinded, crossover study, we assessed the effect of “real” repetitive transcranial magnetic stimulation (rTMS) versus “sham” rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD). Ten patients with PD and prominent dyskinesias had rTMS (1,800 pulses; 1 Hz rate) delivered over the motor cortex for 4 consecutive days twice, once real stimuli and once sham stimulation were used; evaluations were done at the baseline and 1 day after the end of each of the treatment series. Direct comparison between sham and real rTMS effects showed no significant difference in clinician‐assessed dyskinesia severity. However, comparison with the baseline showed small but significant reduction in dyskinesia severity following real rTMS but not placebo. The major effect was on dystonia subscore. Similarly, in patient diaries, although both treatments caused reduction in subjective dyskinesia scores during the days of intervention, the effect was sustained for 3 days after the intervention for the real rTMS only. Following rTMS, no side effects and no adverse effects on motor function and PD symptoms were noted. The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low‐frequency rTMS on dyskinesias in PD. The effects may be further exploited for potential therapeutic uses. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22348
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000C56
- to stream Istex, to step Curation: 000C56
- to stream Istex, to step Checkpoint: 000C86
- to stream PubMed, to step Corpus: 001F62
- to stream PubMed, to step Curation: 001F62
- to stream PubMed, to step Checkpoint: 001B92
- to stream Ncbi, to step Merge: 002401
- to stream Ncbi, to step Curation: 002401
- to stream Ncbi, to step Checkpoint: 002401
- to stream Main, to step Merge: 002945
- to stream Main, to step Curation: 002084
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Repetitive transcranial magnetic stimulation for levodopa‐induced dyskinesias in Parkinson's disease</title>
<author><name sortKey="Filipovi, Sasa R" sort="Filipovi, Sasa R" uniqKey="Filipovi S" first="Saša R." last="Filipovi">Saša R. Filipovi</name>
</author>
<author><name sortKey="Rothwell, John C" sort="Rothwell, John C" uniqKey="Rothwell J" first="John C." last="Rothwell">John C. Rothwell</name>
</author>
<author><name sortKey="Van De Warrenburg, Bart P" sort="Van De Warrenburg, Bart P" uniqKey="Van De Warrenburg B" first="Bart P." last="Van De Warrenburg">Bart P. Van De Warrenburg</name>
</author>
<author><name sortKey="Bhatia, Kailash" sort="Bhatia, Kailash" uniqKey="Bhatia K" first="Kailash" last="Bhatia">Kailash Bhatia</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:FE0418C4633CE28DE9587EE8D6E478381B1FC835</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1002/mds.22348</idno>
<idno type="url">https://api.istex.fr/document/FE0418C4633CE28DE9587EE8D6E478381B1FC835/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000C56</idno>
<idno type="wicri:Area/Istex/Curation">000C56</idno>
<idno type="wicri:Area/Istex/Checkpoint">000C86</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Filipovi S:repetitive:transcranial:magnetic</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:18951540</idno>
<idno type="wicri:Area/PubMed/Corpus">001F62</idno>
<idno type="wicri:Area/PubMed/Curation">001F62</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001B92</idno>
<idno type="wicri:Area/Ncbi/Merge">002401</idno>
<idno type="wicri:Area/Ncbi/Curation">002401</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002401</idno>
<idno type="wicri:Area/Main/Merge">002945</idno>
<idno type="wicri:Area/Main/Curation">002084</idno>
<idno type="wicri:Area/Main/Exploration">002084</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Repetitive transcranial magnetic stimulation for levodopa‐induced dyskinesias in Parkinson's disease</title>
<author><name sortKey="Filipovi, Sasa R" sort="Filipovi, Sasa R" uniqKey="Filipovi S" first="Saša R." last="Filipovi">Saša R. Filipovi</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Burden Neurological Institute, Frenchay Hospital, Bristol</wicri:regionArea>
<wicri:noRegion>Bristol</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rothwell, John C" sort="Rothwell, John C" uniqKey="Rothwell J" first="John C." last="Rothwell">John C. Rothwell</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van De Warrenburg, Bart P" sort="Van De Warrenburg, Bart P" uniqKey="Van De Warrenburg B" first="Bart P." last="Van De Warrenburg">Bart P. Van De Warrenburg</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Neurology, Radboud University Nijmegen Medical Centre, Nijmegen</wicri:regionArea>
<placeName><settlement type="city">Nimègue</settlement>
<region type="province" nuts="2">Gueldre</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bhatia, Kailash" sort="Bhatia, Kailash" uniqKey="Bhatia K" first="Kailash" last="Bhatia">Kailash Bhatia</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-01-30">2009-01-30</date>
<biblScope unit="vol">24</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="246">246</biblScope>
<biblScope unit="page" to="253">253</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">FE0418C4633CE28DE9587EE8D6E478381B1FC835</idno>
<idno type="DOI">10.1002/mds.22348</idno>
<idno type="ArticleID">MDS22348</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Cross-Over Studies</term>
<term>Drug Therapy, Combination</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Dyskinesia, Drug-Induced (therapy)</term>
<term>Female</term>
<term>Humans</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Medical Records</term>
<term>Middle Aged</term>
<term>Motor Cortex (physiopathology)</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson's disease</term>
<term>Severity of Illness Index</term>
<term>Single-Blind Method</term>
<term>Transcranial Magnetic Stimulation (methods)</term>
<term>Treatment Outcome</term>
<term>dyskinesia</term>
<term>placebo</term>
<term>transcranial magnetic stimulation</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Transcranial Magnetic Stimulation</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Motor Cortex</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Cross-Over Studies</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Medical Records</term>
<term>Middle Aged</term>
<term>Severity of Illness Index</term>
<term>Single-Blind Method</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In a placebo‐controlled, single‐blinded, crossover study, we assessed the effect of “real” repetitive transcranial magnetic stimulation (rTMS) versus “sham” rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD). Ten patients with PD and prominent dyskinesias had rTMS (1,800 pulses; 1 Hz rate) delivered over the motor cortex for 4 consecutive days twice, once real stimuli and once sham stimulation were used; evaluations were done at the baseline and 1 day after the end of each of the treatment series. Direct comparison between sham and real rTMS effects showed no significant difference in clinician‐assessed dyskinesia severity. However, comparison with the baseline showed small but significant reduction in dyskinesia severity following real rTMS but not placebo. The major effect was on dystonia subscore. Similarly, in patient diaries, although both treatments caused reduction in subjective dyskinesia scores during the days of intervention, the effect was sustained for 3 days after the intervention for the real rTMS only. Following rTMS, no side effects and no adverse effects on motor function and PD symptoms were noted. The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low‐frequency rTMS on dyskinesias in PD. The effects may be further exploited for potential therapeutic uses. © 2008 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Pays-Bas</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
<li>Gueldre</li>
</region>
<settlement><li>Londres</li>
<li>Nimègue</li>
</settlement>
</list>
<tree><country name="Royaume-Uni"><noRegion><name sortKey="Filipovi, Sasa R" sort="Filipovi, Sasa R" uniqKey="Filipovi S" first="Saša R." last="Filipovi">Saša R. Filipovi</name>
</noRegion>
<name sortKey="Bhatia, Kailash" sort="Bhatia, Kailash" uniqKey="Bhatia K" first="Kailash" last="Bhatia">Kailash Bhatia</name>
<name sortKey="Rothwell, John C" sort="Rothwell, John C" uniqKey="Rothwell J" first="John C." last="Rothwell">John C. Rothwell</name>
<name sortKey="Van De Warrenburg, Bart P" sort="Van De Warrenburg, Bart P" uniqKey="Van De Warrenburg B" first="Bart P." last="Van De Warrenburg">Bart P. Van De Warrenburg</name>
</country>
<country name="Pays-Bas"><region name="Gueldre"><name sortKey="Van De Warrenburg, Bart P" sort="Van De Warrenburg, Bart P" uniqKey="Van De Warrenburg B" first="Bart P." last="Van De Warrenburg">Bart P. Van De Warrenburg</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002084 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002084 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:FE0418C4633CE28DE9587EE8D6E478381B1FC835 |texte= Repetitive transcranial magnetic stimulation for levodopa‐induced dyskinesias in Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |